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EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS
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vices University of the Health Science, 4301 Jones Bridge Road,
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Abstract—Nitric oxide has been implicated in the pathogen-
esis of multiple sclerosis. However, it is still unclear whether
nitric oxide plays a protective role or is deleterious. We have
previously shown that peroxynitrite, a reaction product of
nitric oxide and superoxide, is toxic to mature oligodendro-
cytes (OLs). The toxicity is mediated by intracellular zinc
release, phosphorylation of extracellular signal-regulated ki-
nase 1/2 (ERK1/2), activation of 12-lipoxygenase (12-LOX)
and the formation of reactive oxygen species (ROS). In this
study, we found that the donors of nitric oxide, dipropylene-
triamine NONOate (DPT NONOate) and diethylenetriamine
NONOate (DETA NONOate), protected OLs from peroxynitrite
or zinc-induced toxicity. The protective mechanisms appear
to be attributable to their inhibition of peroxynitrite- or zinc-
induced ERK1/2 phosphorylation and 12-LOX activation. In
cultures of mature OLs exposed to lipopolysaccharide (LPS),
induction of inducible nitric oxide synthase (iNOS) generated
nitric oxide and rendered OLs resistant to peroxynitrite-in-
duced toxicity. The protection was eliminated when 1400W, a
specific inhibitor of iNOS, was co-applied with LPS. Using
MOG35-55-induced experimental autoimmune encephalomy-
elitis (EAE), an animal model of multiple sclerosis, we found
that nitrotyrosine immunoreactivity, an indicator of peroxyni-
trite formation, was increased in the spinal cord white matter,
which correlated with the loss of mature OLs. Targeted gene
deletion of the NADPH oxidase component gp91phox re-
duced clinical scores, the formation of nitrotyrosine and the
loss of mature OLs. These results suggest that blocking the
formation specifically of peroxynitrite, rather than nitric ox-
ide, may be a protective strategy against oxidative stress
induced toxicity to OLs. Published by Elsevier Ltd on behalf
of IBRO.
Key words: nitric oxide, peroxynitrite, NADPH oxidase, zinc,
oligodendrocytes, experimental autoimmune encephalomy-
elitis.
Upregulation of inducible nitric oxide synthase (iNOS) and
the generation of nitric oxide (NO) in reactive microglia/
macrophages is a common feature in multiple sclerosis
(MS) (Smith and Lassmann, 2002; Hill et al., 2004; Saha
and Pahan, 2006). Although there is an increased under-
standing as to the physiological and pathological proper-
ties of nitric oxide in health and disease, the role of NO in
the pathogenesis of MS is still not well defined (Encinas et
al., 2005; Willenborg et al., 2007). The sources of NO, the
amount and sites of NO production, and the molecules NO
reacts with might contribute to the great variability of the
disease promoting or suppressing effects in MS.
NO is synthesized from the amino acid L-arginine by
NO synthase (NOS). There are three major isoforms of
NOS: neuronal NOS (nNOS), endothelial NOS (eNOS)
and inducible NOS (iNOS). nNOS and eNOS are consti-
tutively expressed and require calcium and calmodulin for
activation, whereas iNOS is largely calcium independent
and induced in inflammatory conditions (Knowles and
Moncada, 1994). Although nNOS and eNOS have been
shown to be elevated in experimental autoimmune en-
cephalomyelitis (EAE), one of the commonly used animal
models of MS (Wu and Tsirka, 2009; Yao et al., 2010),
iNOS induction in reactive microglia/macrophages and as-
trocytes is believed to be the predominant source of NO
(Broholm et al., 2004; Sun et al., 2010). It is known that NO
is neither a potent oxidant nor a strong reductant (Calabr-
ese et al., 2009), but it can rapidly react with superoxide to
produce the powerful oxidant peroxynitrite (Beckman et al.,
1990; Pacher et al., 2007). Uric acid, a competitive inhibitor
of tyrosine nitration by peroxynitrite (Robinson et al.,
2004), and FeTPPS, a decomposition catalyst of peroxyni-
trite (Misko et al., 1998), have been shown to be protective
in the EAE animal models of MS (Hooper et al., 1998;
Cross et al., 2000; Hooper et al., 2000; Bolton et al., 2008).
These results are consistent with the findings that patients
with MS and hyperuricemia are mutually exclusive (Spitsin
et al., 2001; Scott et al., 2002). Although several studies
suggest that inhibitors of iNOS ameliorate EAE (Brenner et
al., 1997; Hooper et al., 1997), mice with targeted gene
deletion of iNOS (iNOS/) are found to have an in-
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creased disease severity (Fenyk-Melody et al., 1998; Sah-
rbacher et al., 1998). These results suggest that the inter-
action and balance between nitric oxide, superoxide and
peroxynitrite might be critical in determining whether the
combined action of these reactive nitrogen and oxygen
species is protective or deleterious.
We have previously shown that peroxynitrite toxicity to
mature oligodendrocytes (OLs) is mediated by intracellular
zinc release, activation of extracellular signal-regulated
kinase 1/2 (ERK1/2), 12-lipoxygenase (12-LOX) and the
formation of reactive oxygen species (ROS) (Zhang et al.,
2006). We also found that 12-LOX activation contributes to
OL toxicity induced by glutathione depletion (Wang et al.,
2004). Similar to 5-LOX (Coffey et al., 2000, 2002), the
activity of 12-LOX is also regulated by the intracellular
redox status (Shornick and Holtzman, 1993), and can be
inhibited by nitric oxide (Nakatsuka and Osawa, 1994;
Fujimoto et al., 1998; Coffey et al., 2001). Therefore, it is
likely that nitric oxide may attenuate peroxynitrite-induced
toxicity to OLs via inhibition of 12-LOX. In this study, we
found that both exogenously applied and endogenously
generated nitric oxide is protective against peroxynitrite
toxicity to OLs. The protective mechanisms appeared to be
attributable to the direct interaction of nitric oxide with
12-LOX and the signaling molecules upstream of 12-LOX
activation. Using myelin oligodendrocyte glycoprotein
(MOG)-induced EAE mouse model, we found that mice
with targeted gene deletion of gp91phox (gp91phox/),
a catalytic component of NADPH oxidase (Babior et al.,
2002), are resistant to EAE. These results suggest that
although peroxynitrite, the reaction product of nitric oxide
and superoxide, is toxic to OLs, nitric oxide per se can
serve as a potent antioxidant and an anti-inflammatory
agent.
EXPERIMENTAL PROCEDURES
Materials
SIN-1, peroxynitrite, diethylamine NONOate (DEA NONOate),
dipropylenetriamine NONOate (DPT NONOate) and diethylenetri-
amine NONOate (DETA NONOate) were obtained from Cayman
Chemical Co. (Ann Arbor, MI, USA). FluoZin-3, RhodZin-3, dihy-
drorhodamine 123 (DHR) and 2=,7=-dichlorohydrofluorescein di-
acetate (DCF) were purchased from Molecular Probes, Inc. (Eu-
gene, OR, USA). All the culture materials were purchased from
Gibco Life Technologies (Grand Island, NY, USA). Platelet-de-
rived growth factor (PDGF), basic fibroblast growth factor (bFGF),
and ciliary neurotrophic factor (CNTF) were purchased from Pe-
protech (Princeton, NJ, USA). All other reagents were obtained
from Sigma (St. Louis, MO, USA).
Oligodendrocyte culture
Primary cultures of OLs were prepared by shaking off the progen-
itor cells from mixed glial cell cultures as previously described
(Wang et al., 2004; Zhang et al., 2006). Briefly, mixed primary glial
cultures were prepared from 3 day-old Sprague–Dawley rats by
dissociation of the brains after they were dissected from the pups.
Cultures were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) containing 20% heat-inactivated fetal bovine serum and
1% penicillin/streptomycin in poly-lysine coated 75 cm2 flasks
incubated in 95% air/5% CO2, at 37 °C. The media were changed
three times per week until the cells were confluent (7–10 days).
The flasks were then shaken for 1 h on an orbital shaker (200 rpm)
at 37 °C to remove microglia. They were then changed to new
media and shaken overnight. The OL progenitor cells were de-
tached from the astrocyte layer and were resuspended and
seeded onto poly-ornithine coated plates [96-well (2105 cells/
plate), 24-well (4105 cells/plate)] in a basal chemically-defined
medium (BDM) [DMEM with 1 mg/ml bovine serum albumin
(BSA), 50 g/ml apo-transferrin, 5 g/ml insulin, 30 nM sodium
selenite, 10 nM biotin, 10 nM hydrocortisone] plus 10 ng/ml of both
PDGF and bFGF. The cells were maintained in BDM and the
medium was half-changed three times per week. For culturing
mature OLs, at day 7 OLs were changed to BDM plus 3,3=,5-
triodo-L-thyronine (T3) (15 nM) and CNTF (10 ng/ml) and were
half-changed three times per week for 2 weeks. At this stage,
more than 95% of the cells were MBP positive (Baud et al., 2004;
Wang et al., 2004) and were used for the experiments. The
contamination of astrocytes and microglia was 1–2%, each.
Toxicity assay
The survival of cells after various treatments in 96-well plates were
evaluated by visual inspection using phase contrast microscopy
and quantified by using Alamar Blue (Trek Diagnostic Systems,
Inc., Westlake, OH, USA), a viability assay that was previously
described and validated by cell counting using Trypan Blue exclu-
sion (Back et al., 1999). In all experiments, the culture plates were
first washed twice with Hank’s Balanced Salt Solution (HBSS)
containing 0.1% BSA and then placed in Earle’s Balanced Salt
Solution (EBSS, which is composed of 116 mM NaCl, 5.4 mM KCl,
1.8 mM CaCl2, 0.8 mM MgSO4, 26 mM NaHCO3, 1 mM NaH2PO4
and 5.5 mM D-glucose). OLs were treated with SIN-1, a peroxyni-
trite donor, peroxynitrite or zinc chloride (ZnCl2) for 2 h, washed
twice with HBSS containing 0.1% BSA, and then placed in BDM
with T3 and CNTF. Unless specifically described, donors of nitric
oxide were applied 15 min before, during and after the cells were
exposed to SIN-1, peroxynitrite or ZnCl2. After the cells were
incubated for 20–24 h, the culture medium was replaced with
EBSS plus a 1:100 dilution of Alamar Blue. After a 2 h exposure,
the fluorescence of the Alamar Blue solution in each well in the
plates was read at room temperature in a fluorescent plate reader
(SpectraMax Germini XS, GMI Inc., MN, USA) with excitation
wavelength at 530 nm and emission wavelength at 590 nm. The
data from Alamar Blue assays matched the results from visual
inspection.
Measurement of intracellular cGMP
Intracellular cGMP content was assayed by enzyme-linked immu-
noassay (Amersham, Piscataway, NJ, USA). Cultures were
washed twice and medium was replaced by EBSS in the absence
or presence of DPT-NONOate, SIN-1, and their combination. The
nonspecific phosphodiesterase inhibitor, 3-isobutyl-1-methylxan-
thine (IBMX) at 100 M was present in all conditions. After 30 min
treatment with DPT-NONOate and SIN-1, medium was replaced
with 200 l of releasing reagent provided in the kit. The plates
were agitated for 20 min at room temperature, and 20 l of
acetylation reagent was added. After 5 min, 50 l samples were
taken for assaying the intracellular content of cGMP.
Fluorescence imaging of intracellular liberation of
zinc
Changes in intracellular free zinc concentration in OLs were mon-
itored with a high affinity, zinc selective indicator, FluoZin-3 (Gee
et al., 2002). OLs in 24-well plates were loaded with FluoZin-3 (1
M) for 30 min, washed with HBSS containing 0.1% BSA, and
then treated with SIN-1 (1 mM) in the absence or presence of
DPT-NONOate (30 M) for 60 min. The fluorescence imaging of
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intracellular zinc was monitored immediately using digital fluores-
cence microscopy (Nikon TE-2000) with a 20 objective (excita-
tion at 485 nm, emission at 530 nm). For all images, the micro-
scope settings, such as brightness, contrast and exposure time,
were held constant to compare the relative intensity of intracellular
zinc fluorescence across all treatment conditions.
For quantitative analysis, OLs in 96-well plates were loaded
with FluoZin-3 (2 M) or RhodZin-3 (2 M) for 30 min, washed
twice, and then treated with SIN-1 (1 mM) in the absence or
presence of DPT-NONOate (30 M) for 60 min. The fluorescence
intensity, an indicator of intracellular zinc liberation, in each well
was read at excitation and emission pairs, 485 nm/530 nm and
550 nm/575 nm, for FluoZin-3 and RhodZin-3, respectively.
Measurement of 12-LOX activity
12-LOX activity was measured by quantifying the major metabolic
product of 12-LOX, 12-hydroxyeicosatetraenoic acid (12-HETE),
by ELISA (Assay Designs Inc., Ann Arbor, MI, USA). OLs were
treated with SIN-1 with/without DPT-NONOate for 60 min. After
the cultures were washed twice with HBSS containing 0.1% BSA,
arachidonic acid (20 M) in EBSS was added to the culture which
was then incubated for 30 min. The medium was then collected,
extracted and assayed for 12-HETE according to the manufactur-
er’s protocol. The concentration of 12-HETE in each sample was
normalized to the sample’s protein concentration.
Measurement of intracellular ROS generation
Intracellular free radical generation was evaluated with DHR and
DCF (Molecular Probes, Eugene, OR, USA) as we previously
described (Wang et al., 2004; Zhang et al., 2006). Briefly, after the
cells in 24-well and 96-well plates were treated with SIN-1 with/
without DPT-NONOate for 60 min, they were loaded with DHR (20
M) or DCF (20 M) for 30 min in EBSS (95% air/5% CO2, 37 °C).
After the loading solution was removed, the cells in the wells were
washed and incubated in EBSS. For fluorescence imaging of the
oxidized DHR, cells in 24-well plates were visualized using a
digital fluorescent microscope (Nikon TE-2000) with a 20 objec-
tive. For all images, the microscope settings, such as brightness,
contrast and exposure time, were held constant to compare the
relative intensity of oxidized rhodamine across all treatment con-
ditions. The DCF fluorescence of the cells in each well was
measured and recorded in the fluorescent plate-reader described
above (with excitation wavelength at 480 nm and emission wave-
length at 530 nm and temperature at 37 °C).
Western blot analyses
At various time points after SIN-1 or zinc treatment, OLs were
placed on ice. Following medium aspiration, cells were washed
once with ice-cold phosphate-buffered saline, and lysed with lysis
buffer containing 20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA,
1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1
mM glycerolphosphate, 1 mM Na3VO4, and 1 mM phenylmethyl-
sulfonyl fluoride. An aliquot of cell lysate was removed for later
protein determination. Cell lysate was mixed with Laemmli buffer,
boiled for 5 min, and stored at 20 °C. Equal amounts of protein
were separated by 4–12% SDS-PAGE and electrotransferred to a
polyvinylidene difluoride (PVDF) membrane. Membranes were
blocked with 5% nonfat milk in Tris-buffered saline containing
0.1% Tween 20 (TBST) for 1 h and then incubated overnight at
4 °C with the primary antibodies for phosphorylated ERK1/2, total
ERK1/2 (Cell Signaling, Beverly, MA, USA) and iNOS (BD Biosci-
ences Pharmingen) diluted at 1:1000 in TBST containing 5% BSA.
After washing four times with TBST, the membrane was incubated
for 1 h at room temperature with a horseradish peroxidase-con-
jugated anti-rabbit secondary antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) diluted at 1:4000. The membranes
were washed again as above and visualized by enhanced chemi-
luminescence (ECL) according to the manufacturer’s protocol
(PerkinElmer Life Sciences).
For protein tyrosine nitration assay in the cell-free system,
BSA (0.5 mg/ml) in EBSS with or without DPT-NONOate, DETA-
NONOate and FeTPPS was exposed to SIN-1 for 1 h, and then
4 Laemmli buffer was added. After the samples were heated for
5 min, 2 g protein per lane was subjected to SDS-PAGE analy-
sis, followed by transfer to PVDF membrane and reacted with a
mouse anti-nitrotyrosine monoclonal antibody (Upstate Biotech-
nology, Lake Placid, NY, USA). Protein was visualized with a
horseradish peroxidase-conjugated sheep anti-mouse secondary
antibody followed by detection with ECL.
Mice
Female 7–9-week-old gp91phox knockout mice (gp91phox/)
on a C57BL/6J background and age matched C57BL/6J control
mice were purchased from The Jackson Laboratory (Bar Harbor,
ME, USA). Animal care and experimental procedures were carried
out in accordance with the NIH guideline and approved by the
Uniformed Services University Animal Care and Use Committee.
Induction and clinical evaluation of EAE
EAE in gp91phox/ and C57BL/6J control mice was induced by
s.c. injection of 200 g MOG peptide 35–55 in Complete Freunds
Adjuvant (CFA, DIFCO) with 500 g Mycobacterium tuberculosis
(DIFCO). Immediately following MOG peptide injection, and 24 h
later, mice were administered with 200 ng pertusis toxin (List
Biological Laboratories, Campbell, CA, USA) i.p. At 1 week after
induction, EAE mice received a booster of 200 g of MOG in
incomplete Freunds Adjuvant without Mycobacterium tuberculo-
sis. For gp91phox/ and control mice without EAE induction,
animals underwent the same procedures, except no MOG peptide
was injected. Each group had eight animals. Animals were mon-
itored blind by two independent observers from day 10 onwards
and neurological signs were assessed as follows: 0, normal
mouse; 1, piloerection, tail weakness; 2, tail paralysis; 3, tail
paralysis plus hind limb weakness/paralysis; 4, tail, hind and fore
limb paralysis; 5, moribund/death, using increments of 0.5 points
for intermediate clinical findings. The onset of EAE was defined as
the first day an animal showed a clinical score 0.5.
Immunohistochemistry (IHC)
Animals were euthanized using a combination of ketamine and
xylazine solution (90 mg ketamine/10 mg xylazine per ml, i.p.),
then intracardially perfused with ice cold 1 M phosphate buffer
followed by 4% paraformaldehyde (Sigma, St. Louis, MO, USA) in
1 M phosphate buffer. Spinal cords were dissected out prior to
post-fixation in 4% paraformaldehyde at 4 °C overnight. Tissue
was then cryoprotected in 30% sucrose (Sigma) in 1 M phosphate
buffer at 4 °C overnight. After being cryoprotected the tissue was
embedded in Tissue Tek OCT (Sakura, Torrance, CA, USA) and
stored at 80 °C until utilization. Transverse sections of lumbar
spinal cords were cut at 14 m with a cryostat (Leica model
CM1900, Bannockburn, IL, USA) and mounted onto Superfrost
plus slides (Fisher, Pittsburgh, PA, USA) for immunohistochemical
analysis. For identification of activated microglia/macrophages,
we used F4/80 antibody (eBioscience, San Diego, CA, USA).
Nitrotyrosine reactivity in spinal cord white matter was examined
using an anti-nitrotyrosine polyclonal antibody. Mature OLs were
stained with antibody for CC1 (Calbiochem, San Diego, CA, USA).
Statistics
Cell densities in lumbar spinal cord white matter were manually
counted with areas measured using Spot 2 software. Statistical
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significance in vitro and in vivo assays was assessed using
ANOVA with the Tukey–Kramer post hoc multiple comparison
test. Statistical analysis was performed using the Instat program
from GraphPad Software (San Diego, CA, USA). Experiments
were performed with triplicate samples, and the data are ex-
pressed as meanSD. All experiments were repeated at least
three times.
RESULTS
Effects of nitric oxide donors on peroxynitrite
toxicity to mature OLs
Although nitric oxide is able to react with superoxide to
form the powerful oxidant, peroxynitrite, nitric oxide per se
can function as an antioxidant (Thomas et al., 2008; Sun et
al., 2010). It has been shown previously that several do-
nors of nitric oxide prevent cysteine depletion induced
toxicity to OLs (Rosenberg et al., 1999). DPT-NONOate
and DETA-NONOate, with half-lives of 3 h and 20 h (Moo-
radian et al., 1995), respectively, had significant protective
effects, whereas DEA-NONOate, with a short half-life of
only 2.1 min (Maragos et al., 1991), did not exert any
protection. The failure of DEA-NONOate to protect OLs
from injury is likely due to the fact that there is no contin-
uous release or sustained effective concentrations of nitric
oxide available to antagonize the late oxidative stress trig-
gered by glutathione depletion. Using the same nitric oxide
donors, we tested the role of nitric oxide on SIN-1, a
peroxynitrite generator, as well as peroxynitrite induced
toxicity to mature OLs. As shown in Fig. 1, DPT-NONOate
and DETA-NONOate protected against SIN-1 or peroxyni-
trite induced toxicity to mature OLs in a concentration-
dependent manner. DPT-NONOate at 30 M near fully
attenuated peroxynitrite toxicity. The maximal protection of
DETA-NONOate was found at 100 M. However, DEA-
NONOate either at 30 M or 100 M did not have any
protective effect.
To exclude the possibility that nitric oxide may react
with peroxynitrite directly, we examined whether protein
nitration evoked by SIN-1 can be altered by the presence
of nitric oxide donors. Consistent with our previous findings
(Zhang and Rosenberg, 2002), SIN-1 at 1 mM caused a
strong tyrosine nitration of BSA in a cell-free system. The
nitration was completely blocked by FeTPPS (10 M), a
decomposition catalyst of peroxynitrite, but not by DPT-
NONOate (30 M and 100 M) or DETA-NONOate (100
M). Protein nitration was not found when the BSA solu-
tion was treated by DPT-NONOate, DETA-NONOate and
FeTPPS themselves (Fig. 2A).
It is known that nitric oxide can activate soluble gua-
nylyl cyclase (sGC), resulting in the production of cGMP
(Murad et al., 1993). If the generation of nitric oxide by
nitric oxide donors is affected by the presence of SIN-1, the
production of cGMP in OLs is likely to be altered. Exposure
of OLs with DPT-NONOate (30 M) or SIN-1 (1 mM) for 30
min caused a four-fold increase in the production of cGMP.
The combination of DPT-NONOate and SIN-1 did not have
any additive or suppressive effect (Fig. 2B). This result
suggests that the effective nitric oxide concentration gen-
erated by DPT-NONOate is not reduced by the presence
of SIN-1.
To further exclude the possibility that a direct interac-
tion of nitric oxide donors with SIN-1 may reduce the
availability of peroxynitrite, donors of nitric oxide were
added at various times after initiation of OLs exposure to
peroxynitrite. Because the half life of peroxynitrite is only a
few seconds at physiological pH (Szabo et al., 2007),
delayed addition of nitric oxide is expected to prevent the
direct interaction of nitric oxide with peroxynitrite. Similar to
the results obtained by co-administration of donors of nitric
oxide and peroxynitrite, delayed addition of DPT-NONOate
(30 M) and DETA-NONOate (100 M) at 30 min following
peroxynitrite exposure significantly protected OLs from
toxicity (Fig. 2C). However, no protection was observed
when nitric oxide donors were added 60 min after per-
oxynitrite treatment (Fig. 2C). These results suggest that
the protective effects of various donors of nitric oxide not
only depend on the amount and the duration of nitric oxide
released, but also depend on the direct interaction of nitric
oxide with the signaling molecules activated at the selec-
tive time window following oxidative stress.
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Fig. 1. Effects of nitric oxide donors on peroxynitrite toxicity to mature
OLs. Mature OLs were exposed to SIN-1 (A) or peroxynitrite (B) alone
or with 30 M and 100 M DEA-NONOate (DEA), DPTA-NONOate
(DPT), or DETA-NONOate (DETA) for 2 h, and at an additional 20–24
h cell death was determined by Alamar Blue reduction. SIN-1 at 1 mM
or peroxynitrite (PN) at 300 M caused near total OL cell death. DEA,
with a half-life in aqueous solution of 2 min, did not have a protective
effect, whereas DPT and DETA, with half-lives in aqueous solutions of
3 and 20 h, respectively, were protective. * P0.05 and *** P0.001
were obtained when the DPT- or the DETA- treated groups were
compared with the SIN-1 (S) or PN group alone. Data shown in (A) and
(B) are pooled from six different experiments. For interpretation of the
references to color in this figure legend, the reader is referred to the
Web version of this article.
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Nitric oxide blocked SIN-1 induced 12-LOX activation
and ROS generation
We have found that peroxynitrite toxicity to mature OLs is
mediated by 12-LOX activation and the subsequent gen-
eration of ROS (Zhang et al., 2006). To test whether the
protective effects of nitric oxide are due to its inhibition of
12-LOX activity and blockade of ROS generation, mature
OLs were treated with SIN-1 for 60 min, and the activity of
12-LOX and the generation of ROS were assessed. Using
ELISA, we examined the activity of 12-LOX by measuring
the 12-LOX metabolic end product, 12-HETE. We found
that exposure of OLs to SIN-1 for 60 min induced a signif-
icant increase of 12-LOX activity (Fig. 3A). The level of
12-LOX activity in SIN-1 (1 mM, 1 h) treated OLs was
1508% (meanSD, n3) of control. DPT-NONOate at
30 M completely blocked SIN-1 induced activation of
12-LOX (Fig. 3A). To test the effect of nitric oxide on ROS
generation, mature OLs were treated with SIN-1 for 60
min, and then exposed to DHR or DCF for 30 min. SIN-1 at
1 mM caused a dramatic increase of ROS generation, as
indicated by the elevation of DHR fluorescence. DPT-
NONOate (30 M), did not cause ROS generation, but
completely blocked the generation of ROS induced by
SIN-1 (Fig. 3B). The same result was also found when the
ROS generation was quantified using DCF as an indicator.
SIN-1 caused a time-dependent increase of ROS genera-
tion, which was almost completely blocked by DPT-NONOate
(Fig. 3C).
DPT-NONOate reduced SIN-1 induced intracellular
zinc release and ERK1/2 phosphorylation
As we have shown previously, 12-LOX activation in mature
OLs induced by SIN-1 occurs downstream of intracellular
zinc release and ERK1/2 phosphorylation (Zhang et al.,
2006). Therefore, it is possible that donors of nitric oxide
may directly interact with these signaling molecules. Ma-
ture OLs were treated with SIN-1 in the absence or pres-
ence of DPT-NONOate (30 M) for various times (0, 15,
30, 60, 90 and 120 min), and then lysed for determining the
levels of the phosphorylated and the total ERK1/2 by west-
ern blot analysis. SIN-1 (1 mM) induced phosphorylation of
ERK1/2 appeared at 60 min, and further increased at 90
min and 120 min. The increased ERK1/2 phosphorylation
was significantly attenuated by DPT-NONOate (30 M)
(Fig. 4A). Using densitometric analysis, we found that
DPT-NONOate resulted in a 40–50% reduction in the ratio
of the phosphorylated and the total ERK1/2 at 60, 90 and
120 min after SIN-1 treatment (Fig. 4B).
Similar to other oxidizing agents (Aizenman et al.,
2000), SIN-1 was also found to liberate zinc from intracel-
Fig. 2. The protective effect of nitric oxide donors on peroxynitrite
toxicity is not due to the direct interaction between nitric oxide and
peroxynitrite. (A) DPT and DETA did not attenuate protein nitration
evoked by SIN-1. BSA (0.5 mg/ml) in EBSS was exposed to SIN-1 (1
mM) for 1 h either alone or in the presence of DPT, DETA or FeTPPS.
BSA nitration caused by SIN-1 was not affected by the presence of
nitric oxide donors, but completely blocked by FeTPPS, a decompo-
sition catalyst of peroxynitrite. A representative experiment of three
that were performed is shown. (B) DPT and SIN-1 enhanced cGMP
accumulation in OLs. OLs were treated with DPT (30 M), SIN-1 (1
mM), DPT plus SIN-1 for 30 min, and then lysed for measurement of
the intracellular cGMP content. DPT and SIN-1 both caused a 4-fold
increase of cGMP. The combination of DPT and SIN-1 had no addi-
tional effect. *** P0.001 was obtained when the DPT, SIN-1, and
DPT plus SIN-1 (DPT/S) treated groups were compared with the
control group. Data shown are pooled from three different experi-
ments. (C) Delayed treatment of DPT or DETA on OL toxicity induced
by peroxynitrite. Cultures that were exposed to 300 M peroxynitrite
(PN) were given DPT (30 M) or DETA (100 M) at various times (0,
30 and 60 min) following PN exposure and the toxicity was assessed
at 24 h. Simultaneous administration of DPT and DETA with PN
resulted in 9811% and 756% protection, respectively. Delayed
addition of DPT or DETA at 30 min following PN exposure also
protected against PN toxicity. Cell survival in the presence of DPT and
DETA was 806% and 3511%, respectively. Protective effects were
not observed when the nitric oxide donors were given at 60 min
following PN exposure. ** P0.01 and *** P0.001 were obtained
when the DPT- and the DETA-treated groups (n3) were compared
with the PN group alone (n3).
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lular stores and zinc containing proteins, such as metallo-
thionins (Zhang et al., 2004; Zhang et al., 2006). It is
known that nitric oxide can cause intracellular zinc release
by nitrosation of the zinc binding proteins (Maret, 2006).
These results lead us to hypothesize that nitric oxide and
peroxynitrite may have an additive or a synergistic effect in
causing intracellular zinc liberation. Surprisingly, DPT-
NONOate (30 M) itself did not cause zinc release. It also
had no effect on zinc liberation induced by SIN-1 (Fig. 4C).
Using a quantitative analysis, we found that treatment with
SIN-1 for 1 h caused a three-fold increase in the intracel-
lular fluorescence intensity of FluoZin-3, which was not
altered by the presence of DPT-NONOate. The same re-
sult was also found when RhodZin-3, another novel and
highly selective zinc indicator (Sensi et al., 2003), was
used (data not shown).
Donors of nitric oxide attenuated ERK1/2
phosphorylation, ROS generation and OL toxicity
induced by exogenous zinc
To further determine whether the protective effects of
nitric oxide on peroxynitrite induced toxicity to mature
OLs are due to their interference with the cell death
pathways triggered by zinc, rather than blocking zinc
release, we tested the effects of nitric oxide donors on
OL toxicity induced by exogenous zinc. Similar to the
protective effects on SIN-1 or peroxynitrite induced tox-
icity, DPT-NONOate and DETA-NONOate showed sig-
nificant protection against OL toxicity induced by ZnCl2
(300 M) (Fig. 5A). On the other hand, DEA-NONOate
had no effect. As suggested previously, the different
efficacy of these donors of nitric oxide might be due to
their different half-lives and the effective concentrations
of nitric oxide interacting with molecules implicated in
cell death. Consistent with the protective mechanisms
against peroxynitrite toxicity, donors of nitric oxide also
attenuated zinc-induced ERK1/2 phosphorylation (Fig.
5B, C) and ROS generation (Fig. 5D).
Mature OLs in culture preconditioned with LPS are
resistant to SIN-1 induced toxicity
It has been demonstrated that the expression of iNOS in
cultures of OLs is not derived from OLs, but from the
contamination of microglia and astrocytes (Hewett et al.,
1999). Our culture preparation of OLs typically contains
more than 95% OLs, 1–2% microglia and 1–2% astro-
cytes (Wang et al., 2004; Zhang et al., 2006). Because
of the presence of only small numbers of microglia and
astrocytes, treatment of these cultures with LPS can
result in iNOS induction and NO production without dam-
aging OLs. We speculated that pretreatment of cultures
with LPS (5 g/ml) for 24 h could enable OLs resistant to
SIN-1 or peroxynitrite induced toxicity. Indeed, we found
that without LPS preconditioning, cell viability in the
presence of SIN-1 (0.5 mM) was 407%, and the cell
viability increased to 8010% when the preconditioned
cultures were exposed to SIN-1 (Fig. 6A). To determine
whether the protective effects of LPS preconditioning is
due to the generation of nitric oxide, rather than other
factors released from reactive microglia, cultures of ma-
ture OLs were also treated with 1400W, a selective
inhibitor of iNOS, in the presence of LPS. As shown in
Fig. 6A, the protection afforded by LPS preconditioning
on SIN-1 induced toxicity was attenuated by 1400W (10
M). 1400W, either used alone or together with LPS, did
not affect the viability of OLs in the absence of SIN-1
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Fig. 3. DPT-NONOate attenuated 12-LOX activation and ROS gen-
eration in OLs induced by SIN-1. (A) DPT blocked activation of 12-LOX
induced by SIN-1. Exposure of SIN-1 (1 mM) to OLs for 1 h induced a
significant increase of 12-LOX activity. DPT (30 M) completely
blocked the activation of 12-LOX induced by SIN-1. ** P0.01 was
obtained when the SIN-1 alone group was compared with the other
groups. The data are pooled from four different experiments. (B) SIN-1
induced ROS generation was blocked by DPT. OLs were treated with
SIN-1 for 60 min in the absence or presence of DPT (30 M) and then
exposed to DHR for 30 min. SIN-1 caused an increase of ROS
generation, which was attenuated by DPT. A representative experi-
ment of three that were performed is shown. (C) OLs were treated with
SIN-1 for 60 min in the absence or presence of DPT (30 M) and then
exposed to DCF for 30 min. SIN-1 caused a time-dependent increase
of ROS generation, which was almost completely blocked by DPT. The
data are pooled from three different experiments. For interpretation of
the references to color in this figure legend, the reader is referred to
the Web version of this article.
S. Li et al. / Neuroscience 184 (2011) 107–119112
(Fig. 6A). Consistently, we also found that SIN-1-in-
duced ERK1/2 phosphorylation in cultures of OLs was
attenuated by LPS pretreatment and the reduction was
reversed when 1400W was co-applied (Fig. 6B). The
effect of 1400W seems to be due to its reduction of iNOS
expression (Fig. 6B) and the production of nitric oxide
(Patel et al., 2004; He et al., 2010). The same results
were also found when the LPS pretreated cultures were
exposed to exogenous zinc (data not shown).
Mice with targeted genes deletion of gp91phox are
resistant to EAE
Nitric oxide has long been suggested to be involved in
the pathogenesis of MS (Bagasra et al., 1995; Hooper et
al., 1997; Giovannoni et al., 1998; Brundin et al., 1999).
However, it is still controversial whether nitric oxide is
protective or detrimental to the disease (Brenner et al.,
1997; Hooper et al., 1997; Fenyk-Melody et al., 1998;
Sahrbacher et al., 1998; Dalton and Wittmer, 2005; Jack
et al., 2007). The switch between the protective and the
toxic effects of nitric oxide seems to be determined, at
least in part, by the simultaneous generation of super-
oxide. NADPH oxidase is the primary source of super-
oxide in reactive microglia/macrophages. To determine
the role of NADPH oxidase in the pathogenesis of MS,
EAE was induced in mice with targeted gene deficiency
of gp91phox, a catalytic component of the NADPH oxi-
dase complex. As shown in Fig. 7, the clinical scores
were significantly reduced in gp91phox/ mice when
compared to the wild type mice after EAE induction.
Consistently, the typical loss of body weight observed in
EAE wild type mice was prevented when EAE was in-
duced in gp91phox/ mice. At 28 days following EAE
induction, the density of mature OLs labeled by CC1 in
the spinal cord white matter was dramatically reduced in
the wild type mice, but not in the knockout animals (Fig.
8A). Immunoreactivity to nitrotyrosine, indicative of per-
oxynitrite formation, was dramatically increased in the
spinal cord white matter of the EAE wild type
mice, which correlated with the loss of mature OLs (Fig.
8B). Nitrotyrosine immunoreactivity was not apparent in
gp91phox/ mice (Fig. 8B). Microglia reactivity ob-
served in the EAE wild type mice was not present in the
gp91phox/ EAE mice (data not shown).
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Fig. 4. DPT-NONOate attenuated SIN-1 induced ERK1/2 phosphorylation and zinc release in OLs. (A) DPT attenuated ERK1/2 phosphorylation
induced by SIN-1. Exposure of SIN-1 (1 mM) to OLs induced time-dependent increase of ERK1/2 phosphorylation. DPT (30 M) significantly
reduced ERK1/2 phosphorylation. p-ERK refers to the phosphorylated ERK. A representative experiment of four that were performed is shown.
(B) The relative intensity of the p-ERK/total ERK at various times following SIN-1 treatment was measured using densitometry. *** P0.001 was
obtained when the DPT plus SIN-1 group (n4) was compared to the SIN-1 alone group (n4) at the corresponding time points. (C) DPT
attenuated the increase of FluoZin-3 fluorescence induced by SIN-1. OLs were treated with SIN-1 (1 mm) for 1 h, and then loaded with FluoZin-3
for 30 min. In the presence of DPT (30 M), the fluorescence observed at 60 min following SIN-1 exposure was reduced. A representative
experiment of three that were performed is shown. (D) OLs in 96-well plates were treated with SIN-1 (1 mm) for 1 h, and then loaded with
FluoZin-3 for 30 min. After washing, the fluorescence intensity (FI) of FluoZin-3 was immediately quantified and recorded using a fluorescence
plate reader. *** P0.001 was obtained when the SIN-1 treated groups were compared to the control groups in the absence and presence of
DPT. The data shown are pooled from three different experiments.
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DISCUSSION
A growing body of evidence has shown that peroxynitrite,
a reaction product between nitric oxide and superoxide
near a diffusion-controlled rate, plays a pathogenic role in
MS and the animal counterpart, EAE (Cross et al., 1997,
1998; Hooper et al., 1998, 2000; Scott et al., 2002; Bolton
et al., 2008). Although the scavengers or the decomposi-
tion catalysts of peroxynitrite are consistently shown to
ameliorate EAE (Cross et al., 2000; Hooper et al., 2000;
Scott et al., 2002; Bolton et al., 2008), pharmacological
inhibitors or genetic deletion of iNOS and NADPH oxidase,
the primary enzymes for nitric oxide and superoxide pro-
duction in reactive microglia or macrophages, often pro-
duce opposing results, with both beneficial and deleterious
effects observed (Brenner et al., 1997; Hooper et al., 1997;
Fenyk-Melody et al., 1998; Sahrbacher et al., 1998; van
der Veen et al., 2000, 2004; Hultqvist et al., 2004). These
results indicate that the interaction and the combined ac-
tion between nitric oxide, superoxide and peroxynitrite are
likely one of the potential determinants in the survival or
death of OLs, the myelin producing cells in the CNS.
Nitric oxide is a weak oxidant, but the simultaneous
generation of superoxide in close proximity to nitric oxide
can result in the production of peroxynitrite, the most po-
tent oxidant so far identified (Beckman et al., 1990; Beck-
man and Koppenol, 1996). Therefore, the outcome of the
prooxidant versus the antioxidant properties of nitric oxide
is highly dependent upon the production of superoxide. If
the ratio of nitric oxide and superoxide is not favorable to
the formation of peroxynitrite, increased production of nitric
oxide may be protective, rather than destructive, when
cells are exposed to the oxidative environments.
It has been reported that nitric oxide and peroxynitrite
have contrasting effects toward axonal injury and demyeli-
nation in MS (van der Veen and Roberts, 1999; Touil et al.,
2001). OLs are found to be resistant to nitric oxide, but
more susceptible to the toxicity of peroxynitrite (Jack et al.,
2007; Bishop et al., 2009). However, the mechanisms
underlying the action of nitric oxide and peroxynitrite in
OLs are unclear. In this study, we have found that ERK1/2
phosphorylation and 12-LOX activation, which are the crit-
ical components of peroxynitrite-mediated OL toxicity
(Zhang et al., 2006), can be attenuated by exogenously, as
well as endogenously generated nitric oxide. Interestingly,
we found that 1400W, a selective iNOS inhibitor, also
attenuated the expression of iNOS as reported by others
(Patel et al., 2004; He et al., 2010). The mechanism for this
inhibition is unclear. It is possible that the initial NO pro-
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Fig. 5. Donors of nitric oxide attenuated zinc-induced toxicity, ERK phosphorylation and ROS accumulation. (A) Mature OLs were exposed to ZnCl2
(300 M) alone or with 30 M and 100 M DEA-NONOate (DEA), DPTA-NONOate (DPT), or DETA-NONOate (DETA) for 2 h, cell death was
assessed at 24 h by assay of Alamar Blue reduction. ZnCl2 at 300 M caused complete OL death. DPT at 30 M and 100 M significantly blocked
zinc induced toxicity to OLs. DETA at 100 M was protective against zinc toxicity, but DEA was without effect. *** P0.001 were obtained when the
DPT- or the DETA- treated groups (n3) were compared with the ZnCl2 alone group (n3). (B) Zinc caused a time-dependent increase of ERK
phosphorylation. DPT attenuated ERK1/2 phosphorylation at 30 min following zinc treatment. A representative experiment of three that were
performed is shown. (C) The relative intensity of the p-ERK/total ERK at various times following zinc treatment was measured using densitometry.
* P0.05 was obtained when the DPT plus zinc group was compared to the zinc alone group at 30 min following treatment. The data shown are pooled
from three different experiments. (D) DPT and DETA, but not DEA attenuated zinc-induced ROS generation. OLs were exposed to ZnCl2 (300 M)
for 90 min, and then the DCF fluorescence intensity (F.I.), an indicator of ROS generation, was quantitatively measured. ** P0.01 and *** P0.001
were obtained when the DPT- and DETA-treated groups (n3) were compared with the ZnCl2 alone group (n3). For interpretation of the references
to color in this figure legend, the reader is referred to the Web version of this article.
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duction from iNOS may lead to the release of cytokines,
which can further enhance the expression of iNOS. The
use of 1400W may interrupt a cycle begetting further in-
flammation and iNOS expression (Patel et al., 2004). Con-
sistent with the role of nitric oxide on cysteine depletion
induced toxicity (Rosenberg et al., 1999), donors of nitric
oxide with half lives of at least hours (such as DPT-
NONOate and DETA-NONOate), but not a few minutes
(such as DEA-NONOate) protected against peroxynitrite or
zinc induced toxicity. It is unlikely that a direct interaction
between nitric oxide and peroxynitrite is attributable to the
observed effect of nitric oxide on the basis of the following
findings: (1) donors of nitric oxide did not affect SIN-1
evoked protein nitration in a cell-free system; (2) nitric
oxide-induced cGMP accumulation was not affected by the
presence of SIN-1; and (3) delayed addition of nitric oxide
donors, which prevents the direct interaction between nitric
oxide and peroxynitrite, also significantly attenuated per-
oxynitrite induced toxicity. These results suggest that the
direct interaction of nitric oxide with the cell death signaling
molecules, rather than with peroxynitrite itself, may con-
tribute to the antioxidant effects of nitric oxide.
Nitric oxide is an important signaling molecule with
diverse biological properties (Calabrese et al., 2007,
2009). Under physiological conditions, nitric oxide can re-
act with iron (II) of the sGC, inducing a conformational
change, and subsequently activating protein kinase G and
protein phosphorylation (Garthwaite and Boulton, 1995).
Fig. 6. LPS pretreatment enabled mature OL cultures resistant to
SIN-1 induced toxicity and ERK1/2 phosphorylation. (A) Mature OL
cultures were treated with LPS (5 g/ml) for 24 h, and then treated with
SIN-1 (0.5 mM) for 2 h. Toxicity was examined at 18–24 h. LPS
preconditioning enabled mature OLs to be resistant to SIN-1 induced
toxicity. The protection was eliminated when 1400W (10 M) was used
together with LPS. 1400W itself did not affect OL toxicity induced by
SIN-1. *** P0.001 was obtained when the LPSSIN-1 group was
compared with the other groups in the presence of SIN-1. The data
shown are pooled from four different experiments. (B) LPS pretreat-
ment enabled OLs resistant to SIN-1 induced ERK1/2 phosphoryla-
tion. OLs were pretreated with LPS, 1400W alone or in combination
(LPSW) for 24 h, followed by 1 h SIN-1 (1 mM) treatment. Cell
lysates were used to detect the expression of iNOS, phosphorylated
ERK1/2 (pERK1/2) and total ERK1/2. -actin was used as a loading
control. Treatment of cultures with LPS for 24 h induced iNOS expres-
sion and attenuated the ERK1/2 phosphorylation induced by SIN-1.
The reduction of ERK1/2 phosphorylation was reversed when the
selective iNOS inhibitor 1400W was co-administered with LPS. Nota-
bly, the expression of iNOS was also inhibited by 1400W. Pretreat-
ment of cultures with 1400W had no effect on iNOS induction and
ERK1/2 phosphorylation induced by SIN-1. LPSW refer to LPS
1400W. A representative experiment of three that were performed is
shown.
Fig. 7. Mice with targeted gene deletion of gp91phox are resistant
to EAE. (A) gp91phox/ mice and wild type C57BL/6J mice
were inoculated with MOG35-55, and clinical scores were assessed
on a daily basis. Clinical scores were significantly decreased in
gp91phox/ EAE mice (n8) when compared to the EAE wild type
mice (n8; * P0.05). (B) Body weight was significantly reduced in
EAE wild type mice compared with EAE gp91phox/, wild type and
gp91phox/ control mice (n8 in each group; * P0.05). For inter-
pretation of the references to color in this figure legend, the reader is
referred to the Web version of this article.
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However, it seems unlikely that activation of sGC contrib-
utes to the protective effect of nitric oxide, because the
protection of nitric oxide against SIN-1 toxicity is not af-
fected by the presence of 1H-[1,2,4] oxadiazolo[4,3-a] qui-
noxaline-1-one (ODQ), a selective inhibitor of sGC (data
not shown). Nitric oxide can also mediate its biological
effects via sGC independent pathways including protein
nitrosation in many different cell types (Chung et al., 2005;
Szabo et al., 2007; Calabrese et al., 2009). This posttrans-
lational modification can either increase or decrease the
protein function depending upon which protein is specifi-
cally targeted. It has been demonstrated that 5-LOX, the
enzyme catalyzing the hydrolysis of arachidonic acid for
the production of inflammatory leukotrienes, can be di-
rectly inhibited by nitric oxide (Coffey et al., 2000, 2002).
Nitric oxide was also reported to directly inhibit the activity
of 12-LOX (Nakatsuka and Osawa, 1994; Fujimoto et al.,
1998; Coffey et al., 2001). The inhibitory action of nitric
oxide to LOXs is suggested to be due to its reaction with
the nonheme ions in the enzymes. It is also likely that
nitrosation of the LOXs contribute to the inhibitory action of
nitric oxide. Similar to the report that 5-LOX can be phos-
phorylated by MAPK-activated protein kinase (Werz et al.,
2000), it is possible that 12-LOX can be directly, or indi-
rectly, phosphorylated by ERK1/2 (Zhang et al., 2006).
Therefore, the inhibitory action of nitric oxide on 12-LOX
may be, at least partially, due to its attenuation of ERK
phosphorylation.
We have previously shown that peroxynitrite toxicity to
mature OLs is mediated by intracellular zinc release
(Zhang et al., 2006). Although the exact sources of labile
zinc is unclear, metallothioneins, the low molecular weight
and cysteine-rich metal binding proteins, may be one of the
major sources from which zinc is released typically in
response to thiol oxidization (Maret, 2000). Similar to the
redox agent 2,2=-dithiodipyridine (DTDP) (Aizenman et al.,
2000), peroxynitrite can oxidize the cysteine residues of
metallothioneins to readily release zinc ions (Zhang et al.,
2006, 2007). Although many studies have suggested that
nitric oxide can also liberate zinc from metallothioneins and
the other intracellular zinc stores (St Croix et al., 2002;
Spahl et al., 2003; Maret, 2006; Suh et al., 2008), we found
the nitric oxide donor DPT-NONOate either used at 30 M
or 100 M (data not shown) did not cause zinc release.
DPT-NONOate had no effect on zinc liberation by per-
oxynitrite suggesting that nitric oxide can interact with the
downstream signaling molecules activated by zinc. The
partial inhibition of ERK and the complete blockage of
12-LOX activity by nitric oxide suggest that nitric oxide may
block 12-LOX activity by its direct inhibition of the enzyme
and its interference with the upstream pathways leading to
12-LOX activation. In addition, the antioxidant effect of
nitric oxide may be also due to its direct reaction with
alkoxyl and peroxyl intermediates during lipid peroxidation
induced by peroxynitrite, thus terminating lipid radical
chain propagated reactions (Rubbo et al., 1994, 2000;
Baker et al., 2009).
EAE induced by myelin proteins is a commonly studied
animal model of MS, which is characterized by T cell
infiltration through a compromised blood–brain barrier. T
cells interact with macrophage/microglia to affect disease
progression by production of cytokines, chemokines, and
nitric oxide. Although the initial response of reactive micro-
glia/macrophages is phagocytosis of damaged cells or
Fig. 8. Targeted gene deletion of gp91phox attenuated the loss of OLs and the formation of nitrotyrosine in the EAE mice spinal cord white matter.
(A) A significant loss of CC1 mature OLs was found in spinal cord white matter of EAE wild type mice, which was prevented in EAE gp91phox/
mice (n8; * P0.05). A lower density of CC1 positive OL cells was readily observed in the dorsal column of EAE wild type mice compared with control
and EAE gp91phox/ mice. (B) Nitrotyrosine immunoreactivity, indicative of peroxynitrite formation, was reduced in the ventral white matter of EAE
gp91phox/ mice compared with the EAE wild type mice. A representative image from eight mice in each group is shown.
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tissues, increased production of the detrimental factors by
microglia/macrophages can cause cytotoxicity. NADPH
oxidase is believed to be the primary superoxide producing
enzyme in reactive microglia and macrophages (Sun et al.,
2007). It is a heterocomplex that is composed of p47phox,
p67phox, gp91phox, p22phox, and rac2 (Rotrosen et al.,
1993). Two of these subunits, p22phox and gp91phox are
integral membrane proteins forming a heterodimeric flavo-
cytochrome that is the catalytic core of the complex. The
remaining components are cytosolic proteins. Upon acti-
vation, these cytosolic proteins translocate to the plasma
membrane and form a functional heteromeric complex that
associates with the membrane-bound heterodimer (Brown
et al., 2003). Activated NADPH oxidase binds FAD and
NADPH, resulting in a flow of electrons to oxygen to yield
superoxide. Studies have shown that pharmacological in-
hibitors or targeted gene deletion of iNOS and gp91phox
are protective against reactive microglia-induced toxicity to
neurons and OLs in culture (Xie et al., 2002; Li et al.,
2005). Although a number of studies have shown that
deletion of iNOS potentiates the disease severity of EAE
(Fenyk-Melody et al., 1998; Sahrbacher et al., 1998; van
der Veen et al., 2000, 2004; Hultqvist et al., 2004; Farias et
al., 2007), the contribution of NADPH oxidase in the patho-
genesis of EAE has not been well elucidated. It has been
reported that targeted gene deletion of p47phox can either
increase or decrease the severity of several autoimmune
diseases (van der Veen et al., 2000, 2004; Hultqvist et al.,
2004). In this study, we found that EAE in gp91phox/
mice is ameliorated, supporting the notion that peroxyni-
trite plays a pathogenic role in EAE. It also suggests that
without oxidation by superoxide, nitric oxide is likely to
have immnosuppresive and anti-inflammatory effects (van
der Veen et al., 2000). Our study also indicates that nitric
oxide can attenuate peroxynitrite toxicity to OLs by directly
targeting the cell death pathways involving ERK1/2 phos-
phorylation and 12-LOX activation. Taken together, these
results suggest that blocking the formation specifically of
peroxynitrite, rather than nitric oxide, may be a protective
strategy against oxidative stress induced toxicity to OLs in
diseases such as MS.
Acknowledgments—This work was supported by grants from the
United Cerebral Palsy Foundation (R-759), the National Multiple
Sclerosis Society (RG3741) and the start-up fund from the Uni-
formed Services University (R070 UX).
REFERENCES
Aizenman E, Stout AK, Hartnett KA, Dineley KE, McLaughlin B, Reyn-
olds IJ (2000) Induction of neuronal apoptosis by thiol oxidation:
putative role of intracellular zinc release. J Neurochem 75:1878–
1888.
Babior BM, Lambeth JD, Nauseef W (2002) The neutrophil NADPH
oxidase. Arch Biochem Biophys 397:342–344.
Back SA, Khan R, Gan X, Rosenberg PA, Volpe JJ (1999) A new
Alamar Blue viability assay to rapidly quantify oligodendrocyte
death. J Neurosci Methods 91:47–54.
Bagasra O, Michaels FH, Zheng YM, Bobroski LE, Spitsin SV, Fu ZF,
Tawadros R, Koprowski H (1995) Activation of the inducible form of
nitric oxide synthase in the brains of patients with multiple sclero-
sis. Proc Natl Acad Sci U S A 92:12041–12045.
Baker PR, Schopfer FJ, O’Donnell VB, Freeman BA (2009) Conver-
gence of nitric oxide and lipid signaling: anti-inflammatory nitro-
fatty acids. Free Radic Biol Med 46:989–1003.
Baud O, Li J, Zhang Y, Neve RL, Volpe JJ, Rosenberg PA (2004) Nitric
oxide-induced cell death in developing oligodendrocytes is asso-
ciated with mitochondrial dysfunction and apoptosis-inducing fac-
tor translocation. Eur J Neurosci 20:1713–1726.
Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA (1990)
Apparent hydroxyl radical production by peroxynitrite: implications
for endothelial injury from nitric oxide and superoxide. Proc Natl
Acad Sci U S A 87:1620–1624.
Beckman JS, Koppenol WH (1996) Nitric oxide, superoxide, and per-
oxynitrite: the good, the bad, and ugly. Am J Physiol 271:
C1424–C1437.
Bishop A, Hobbs KG, Eguchi A, Jeffrey S, Smallwood L, Pennie C,
Anderson J, Estevez AG (2009) Differential sensitivity of oligoden-
drocytes and motor neurons to reactive nitrogen species: implica-
tions for multiple sclerosis. J Neurochem 109:93–104.
Bolton C, Scott GS, Smith T, Flower RJ (2008) The acute and chronic
phases of chronic relapsing experimental autoimmune encephalo-
myelitis (CR EAE) are ameliorated by the peroxynitrite decompo-
sition catalyst, 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrina-
toiron (III) chloride, (FeTPPS). Eur J Pharmacol 601:88–93.
Brenner T, Brocke S, Szafer F, Sobel RA, Parkinson JF, Perez DH,
Steinman L (1997) Inhibition of nitric oxide synthase for treatment
of experimental autoimmune encephalomyelitis. J Immunol 158:
2940–2946.
Broholm H, Andersen B, Wanscher B, Frederiksen JL, Rubin I, Pak-
kenberg B, Larsson HB, Lauritzen M (2004) Nitric oxide synthase
expression and enzymatic activity in multiple sclerosis. Acta Neurol
Scand 109:261–269.
Brown GE, Stewart MQ, Liu H, Ha VL, Yaffe MB (2003) A novel assay
system implicates PtdIns(3,4)P(2), PtdIns(3)P, and PKC delta in
intracellular production of reactive oxygen species by the NADPH
oxidase. Mol Cell 11:35–47.
Brundin L, Morcos E, Olsson T, Wiklund NP, Andersson M (1999)
Increased intrathecal nitric oxide formation in multiple sclerosis;
cerebrospinal fluid nitrite as activity marker. Eur J Neurol 6:
585–590.
Calabrese V, Cornelius C, Rizzarelli E, Owen JB, Dinkova-Kostova
AT, Butterfield DA (2009) Nitric oxide in cell survival: a janus
molecule. Antioxid Redox Signal 11:2717–2739.
Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA,
Stella AM (2007) Nitric oxide in the central nervous system: neu-
roprotection versus neurotoxicity. Nat Rev Neurosci 8:766–775.
Chung KK, Dawson TM, Dawson VL (2005) Nitric oxide, S-nitrosyla-
tion and neurodegeneration. Cell Mol Biol Noisy-le-grand
51:247–254.
Coffey MJ, Natarajan R, Chumley PH, Coles B, Thimmalapura PR,
Nowell M, Kuhn H, Lewis MJ, Freeman BA, O’Donnell VB (2001)
Catalytic consumption of nitric oxide by 12/15- lipoxygenase: inhi-
bition of monocyte soluble guanylate cyclase activation. Proc Natl
Acad Sci U S A 98:8006–8011.
Coffey MJ, Phare SM, Peters-Golden M (2000) Prolonged exposure to
lipopolysaccharide inhibits macrophage 5-lipoxygenase meta-
bolism via induction of nitric oxide synthesis. J Immunol 165:
3592–3598.
Coffey MJ, Phare SM, Peters-Golden M (2002) Interaction between
nitric oxide, reactive oxygen intermediates, and peroxynitrite in the
regulation of 5-lipoxygenase metabolism. Biochim Biophys Acta
1584:81–90.
Cross AH, Manning PT, Keeling RM, Schmidt RE, Misko TP (1998)
Peroxynitrite formation within the central nervous system in active
multiple sclerosis. J Neuroimmunol 88:45–56.
Cross AH, Manning PT, Stern MK, Misko TP (1997) Evidence for the
production of peroxynitrite in inflammatory CNS demyelination.
J Neuroimmunol 80:121–130.
S. Li et al. / Neuroscience 184 (2011) 107–119 117
Cross AH, San M, Stern MK, Keeling RM, Salvemini D, Misko TP
(2000) A catalyst of peroxynitrite decomposition inhibits murine
experimental autoimmune encephalomyelitis. J Neuroimmunol
107:21–28.
Dalton DK, Wittmer S (2005) Nitric-oxide-dependent and independent
mechanisms of protection from CNS inflammation during Th1-
mediated autoimmunity: evidence from EAE in iNOS KO mice.
J Neuroimmunol 160:110–121.
Encinas JM, Manganas L, Enikolopov G (2005) Nitric oxide and mul-
tiple sclerosis. Curr Neurol Neurosci Rep 5:232–238.
Farias AS, de la Hoz C, Castro FR, Oliveira EC, Ribeiro dos Reis JR,
Silva JS, Langone F, Santos LM (2007) Nitric oxide and TNFalpha
effects in experimental autoimmune encephalomyelitis demyelina-
tion. Neuroimmunomodulation 14:32–38.
Fenyk-Melody JE, Garrison AE, Brunnert SR, Weidner JR, Shen F,
Shelton BA, Mudgett JS (1998) Experimental autoimmune enceph-
alomyelitis is exacerbated in mice lacking the NOS2 gene. J Im-
munol 160:2940–2946.
Fujimoto Y, Tagano S, Ogawa K, Sakuma S, Fujita T (1998) Compar-
ison of the effects of nitric oxide and peroxynitrite on the 12-
lipoxygenase and cyclooxygenase metabolism of arachidonic acid
in rabbit platelets. Prostaglandins Leukot Essent Fatty Acids
59:95–100.
Garthwaite J, Boulton CL (1995) Nitric oxide signaling in the central
nervous system. Annu Rev Physiol 57:683–706.
Gee KR, Zhou ZL, Qian WJ, Kennedy R (2002) Detection and imaging
of zinc secretion from pancreatic beta-cells using a new fluorescent
zinc indicator. J Am Chem Soc 124:776–778.
Giovannoni G, Heales SJ, Land JM, Thompson EJ (1998) The poten-
tial role of nitric oxide in multiple sclerosis. Mult Scler 4:212–216.
He YF, Chen HJ, Qian LH, Chen GY (2010) Effect of 1400W on
blocking lipopolysaccharide-induced microglial toxicity to preoligo-
dendrocytes. World J Pediatr 6:249–254.
Hewett JA, Hewett SJ, Winkler S, Pfeiffer SE (1999) Inducible nitric
oxide synthase expression in cultures enriched for mature oligo-
dendrocytes is due to microglia. J Neurosci Res 56:189–198.
Hill KE, Zollinger LV, Watt HE, Carlson NG, Rose JW (2004) Inducible
nitric oxide synthase in chronic active multiple sclerosis plaques:
distribution, cellular expression and association with myelin dam-
age. J Neuroimmunol 151:171–179.
Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST, Kean R,
Champion JM, Sarker AB, Bobroski L, Farber JL, Akaike T, Maeda
H, Koprowski H (1997) Prevention of experimental allergic enceph-
alomyelitis by targeting nitric oxide and peroxynitrite: implications
for the treatment of multiple sclerosis. Proc Natl Acad Sci U S A
94:2528–2533.
Hooper DC, Scott GS, Zborek A, Mikheeva T, Kean RB, Koprowski H,
Spitsin SV (2000) Uric acid, a peroxynitrite scavenger, inhibits CNS
inflammation, blood-CNS barrier permeability changes, and tissue
damage in a mouse model of multiple sclerosis. FASEB J
14:691–698.
Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM,
Chaudhry I, Koprowski H (1998) Uric acid, a natural scavenger of
peroxynitrite, in experimental allergic encephalomyelitis and multi-
ple sclerosis. Proc Natl Acad Sci U S A 95:675–680.
Hultqvist M, Olofsson P, Holmberg J, Backstrom BT, Tordsson J,
Holmdahl R (2004) Enhanced autoimmunity, arthritis, and enceph-
alomyelitis in mice with a reduced oxidative burst due to a mutation
in the Ncf1 gene. Proc Natl Acad Sci U S A 101:12646–12651.
Jack C, Antel J, Bruck W, Kuhlmann T (2007) Contrasting potential of
nitric oxide and peroxynitrite to mediate oligodendrocyte injury in
multiple sclerosis. Glia 55:926–934.
Knowles RG, Moncada S (1994) Nitric oxide synthases in mammals.
Biochem J 298 (Pt 2):249–258.
Li J, Baud O, Vartanian T, Volpe JJ, Rosenberg PA (2005) Peroxyni-
trite generated by inducible nitric oxide synthase and NADPH
oxidase mediates microglial toxicity to oligodendrocytes. Proc Natl
Acad Sci U S A 102:9936–9941.
Maragos CM, Morley D, Wink DA, Dunams TM, Saavedra JE, Hoffman
A, Bove AA, Isaac L, Hrabie JA, Keefer LK (1991) Complexes
of NO with nucleophiles as agents for the controlled biological
release of nitric oxide. Vasorelaxant effects. J Med Chem 34:
3242–3247.
Maret W (2000) The function of zinc metallothionein: a link between
cellular zinc and redox state. J Nutr 130:1455S–1458S.
Maret W (2006) Zinc coordination environments in proteins as redox
sensors and signal transducers. Antioxid Redox Signal 8:1419–
1441.
Misko TP, Highkin MK, Veenhuizen AW, Manning PT, Stern MK,
Currie MG, Salvemini D (1998) Characterization of the cytoprotec-
tive action of peroxynitrite decomposition catalysts. J Biol Chem
273:15646–15653.
Mooradian DL, Hutsell TC, Keefer LK (1995) Nitric oxide (NO) donor
molecules: effect of NO release rate on vascular smooth muscle
cell proliferation in vitro. J Cardiovasc Pharmacol 25:674–678.
Murad F, Forstermann U, Nakane M, Pollock J, Tracey R, Matsumoto
T, Buechler W (1993) The nitric oxide-cyclic GMP signal transduc-
tion system for intracellular and intercellular communication. Adv
Second Messenger Phosphoprotein Res 28:101–109.
Nakatsuka M, Osawa Y (1994) Selective inhibition of the 12-lipoxy-
genase pathway of arachidonic acid metabolism by L-arginine or
sodium nitroprusside in intact human platelets. Biochem Biophys
Res Commun 200:1630–1634.
Pacher P, Beckman JS, Liaudet L (2007) Nitric oxide and peroxynitrite
in health and disease. Physiol Rev 87:315–424.
Patel P, Qi WN, Allen DM, Chen LE, Seaber AV, Stamler JS, Urbaniak
JR (2004) Inhibition of iNOS with 1400W improves contractile
function and alters nos gene and protein expression in reperfused
skeletal muscle. Microsurgery 24:324–331.
Robinson KM, Morre JT, Beckman JS (2004) Triuret: a novel product
of peroxynitrite-mediated oxidation of urate. Arch Biochem Biophys
423:213–217.
Rosenberg PA, Li Y, Ali S, Altiok N, Back SA, Volpe JJ (1999) Intra-
cellular redox state determines whether nitric oxide is toxic or
protective to rat oligodendrocytes in culture. J Neurochem 73:
476–484.
Rotrosen D, Yeung CL, Katkin JP (1993) Production of recombinant
cytochrome b558 allows reconstitution of the phagocyte NADPH
oxidase solely from recombinant proteins. J Biol Chem 268:
14256–14260.
Rubbo H, Radi R, Anselmi D, Kirk M, Barnes S, Butler J, Eiserich JP,
Freeman BA (2000) Nitric oxide reaction with lipid peroxyl radicals
spares alpha-tocopherol during lipid peroxidation. Greater oxidant
protection from the pair nitric oxide/alpha-tocopherol than alpha-
tocopherol/ascorbate. J Biol Chem 275:10812–10818.
Rubbo H, Radi R, Trujillo M, Telleri R, Kalyanaraman B, Barnes S, Kirk
M, Freeman BA (1994) Nitric oxide regulation of superoxide and
peroxynitrite-dependent lipid peroxidation. Formation of novel ni-
trogen-containing oxidized lipid derivatives. J Biol Chem 269:
26066–26075.
Saha RN, Pahan K (2006) Regulation of inducible nitric oxide synthase
gene in glial cells. Antioxid Redox Signal 8:929–947.
Sahrbacher UC, Lechner F, Eugster HP, Frei K, Lassmann H, Fontana
A (1998) Mice with an inactivation of the inducible nitric oxide
synthase gene are susceptible to experimental autoimmune en-
cephalomyelitis. Eur J Immunol 28:1332–1338.
Scott GS, Spitsin SV, Kean RB, Mikheeva T, Koprowski H, Hooper DC
(2002) Therapeutic intervention in experimental allergic encepha-
lomyelitis by administration of uric acid precursors. Proc Natl Acad
Sci U S A 99:16303–16308.
Sensi SL, Ton-That D, Weiss JH, Rothe A, Gee KR (2003) A new
mitochondrial fluorescent zinc sensor. Cell Calcium 34:281–284.
Shornick LP, Holtzman MJ (1993) A cryptic, microsomal-type arachid-
onate 12-lipoxygenase is tonically inactivated by oxidation-reduc-
tion conditions in cultured epithelial cells. J Biol Chem 268:
371–376.
S. Li et al. / Neuroscience 184 (2011) 107–119118
Smith KJ, Lassmann H (2002) The role of nitric oxide in multiple
sclerosis. Lancet Neurol 1:232–241.
Spahl DU, Berendji-Grun D, Suschek CV, Kolb-Bachofen V, Kroncke
KD (2003) Regulation of zinc homeostasis by inducible NO syn-
thase-derived NO: nuclear metallothionein translocation and
intranuclear Zn2 release. Proc Natl Acad Sci U S A 100:
13952–13957.
Spitsin S, Hooper DC, Leist T, Streletz LJ, Mikheeva T, Koprowskil H
(2001) Inactivation of peroxynitrite in multiple sclerosis patients
after oral administration of inosine may suggest possible ap-
proaches to therapy of the disease. Mult Scler 7:313–319.
St Croix CM, Wasserloos KJ, Dineley KE, Reynolds IJ, Levitan ES, Pitt
BR (2002) Nitric oxide-induced changes in intracellular zinc ho-
meostasis are mediated by metallothionein/thionein. Am J Physiol
Lung Cell Mol Physiol 282:L185–L192.
Suh SW, Hamby AM, Gum ET, Shin BS, Won SJ, Sheline CT, Chan
PH, Swanson RA (2008) Sequential release of nitric oxide, zinc,
and superoxide in hypoglycemic neuronal death. J Cereb Blood
Flow Metab 28:1697–1706.
Sun GY, Horrocks LA, Farooqui AA (2007) The roles of NADPH
oxidase and phospholipases A2 in oxidative and inflammatory
responses in neurodegenerative diseases. J Neurochem 103:
1–16.
Sun J, Druhan LJ, Zweier JL (2010) Reactive oxygen and nitrogen
species regulate inducible nitric oxide synthase function shifting
the balance of nitric oxide and superoxide production. Arch
Biochem Biophys 494:130–137.
Szabo C, Ischiropoulos H, Radi R (2007) Peroxynitrite: biochemistry,
pathophysiology and development of therapeutics. Nat Rev Drug
Discov 6:662–680.
Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH,
Donzelli S, Hussain P, Vecoli C, Paolocci N, Ambs S, Colton CA,
Harris CC, Roberts DD, Wink DA (2008) The chemical biology of
nitric oxide: implications in cellular signaling. Free Radic Biol Med
45:18–31.
Touil T, Deloire-Grassin MS, Vital C, Petry KG, Brochet B (2001) In
vivo damage of CNS myelin and axons induced by peroxynitrite.
Neuroreport 12:3637–3644.
van der Veen RC, Dietlin TA, Hofman FM, Pen L, Segal BH, Holland
SM (2000) Superoxide prevents nitric oxide-mediated suppression
of helper T lymphocytes: decreased autoimmune encephalomyeli-
tis in nicotinamide adenine dinucleotide phosphate oxidase knock-
out mice. J Immunol 164:5177–5183.
van der Veen RC, Dietlin TA, Karapetian A, Holland SM, Hofman FM
(2004) Extra-cellular superoxide promotes T cell expansion
through inactivation of nitric oxide. J Neuroimmunol 153:183–189.
van der Veen RC, Roberts LJ (1999) Contrasting roles for nitric oxide
and peroxynitrite in the peroxidation of myelin lipids. J Neuroim-
munol 95:1–7.
Wang H, Li J, Follett PL, Zhang Y, Cotanche DA, Jensen FE, Volpe JJ,
Rosenberg PA (2004) 12-Lipoxygenase plays a key role in cell
death caused by glutathione depletion and arachidonic acid in rat
oligodendrocytes. Eur J Neurosci 20:2049–2058.
Werz O, Klemm J, Samuelsson B, Radmark O (2000) 5-Lipoxygenase
is phosphorylated by p38 kinase-dependent MAPKAP kinases.
Proc Natl Acad Sci U S A 97:5261–5266.
Willenborg DO, Staykova M, Fordham S, O’Brien N, Linares D (2007)
The contribution of nitric oxide and interferon gamma to the regu-
lation of the neuro-inflammation in experimental autoimmune en-
cephalomyelitis. J Neuroimmunol 191:16–25.
Wu M, Tsirka SE (2009) Endothelial NOS-deficient mice reveal dual
roles for nitric oxide during experimental autoimmune encephalo-
myelitis. Glia 57:1204–1215.
Xie Z, Wei M, Morgan TE, Fabrizio P, Han D, Finch CE, Longo VD
(2002) Peroxynitrite mediates neurotoxicity of amyloid beta-pep-
tide1-42- and lipopolysaccharide-activated microglia. J Neurosci
22:3484–3492.
Yao S, Pandey P, Ljunggren-Rose A, Sriram S (2010) LPS mediated
injury to oligodendrocytes is mediated by the activation of nNOS:
relevance to human demyelinating disease. Nitric Oxide 22:
197–204.
Zhang Y, Aizenman E, DeFranco DB, Rosenberg PA (2007) Intracel-
lular zinc release, 12-lipoxygenase activation and MAPK depen-
dent neuronal and oligodendroglial death. Mol Med 13:350–355.
Zhang Y, Rosenberg PA (2002) The essential nutrient pyrroloquinoline
quinone may act as a neuroprotectant by suppressing peroxynitrite
formation. Eur J Neurosci 16:1015–1024.
Zhang Y, Wang H, Li J, Dong L, Xu P, Chen W, Neve RL, Volpe JJ,
Rosenberg PA (2006) Intracellular zinc release and ERK phos-
phorylation are required upstream of 12-lipoxygenase activation in
peroxynitrite toxicity to mature rat oligodendrocytes. J Biol Chem
281:9460–9470.
Zhang Y, Wang H, Li J, Jimenez DA, Levitan ES, Aizenman E, Rosen-
berg PA (2004) Peroxynitrite-induced neuronal apoptosis is medi-
ated by intracellular zinc release and 12-lipoxygenase activation.
J Neurosci 24:10616–10627.
(Accepted 5 April 2011)
(Available online 13 April 2011)
S. Li et al. / Neuroscience 184 (2011) 107–119 119
